GILD - Gilead Sciences Inc Year-over-year net earnings per share growth for the last 12 months

Historical quarterly EPS growth demonstrates profit dynamics as Gilead Sciences, Inc. (GILD) pivots toward CAR-T therapy and oncology, with -19.80 reflecting the most recent metric value. Leadership in virology is sustained by recruiting top scientists and providing high compensation. Business development relies on strategic partnerships with startups and joint clinical trials.
Summary analytical data breakdowns for gilead.com (GILD)

For Gilead Sciences, Inc. (GILD), profit dynamics determine the effectiveness of the transition from HIV therapy dominance to the oncology segment. This metric is calculated as the percentage change in net earnings per share compared to the same period last year. By analyzing this quarterly earnings per share chart, investors can assess the real speed of capital growth. A positive trend confirms successful portfolio diversification via Trodelvy. The stability of this metric guarantees the sustainability of dividend payments.